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INTRODUCTION 
 
 
 Chronic Obstructive Pulmonary Diseases (COPD) has been 
defined by the Global Initiative for chronic obstructive lung disease 
(GOLD) as “a disease stage characterized by air flow limitation that is 
not fully reversible” 1 
 Chronic Obstructive Pulmonary Diseases includes (i) Emphysema 
defined as the permanent abnormal distension of the air spaces distal to 
the terminal bronchioles accompanied by destruction of their wall 
without fibrosis.   (ii) Chronic Bronchitis defined on the presence of 
Chronic productive cough on most days for 3 months in each of two 
consecutive years.  (iii) Small airway disease 2 in which small 
bronchioles are narrowed. 
 Excluded from this definition is Bronchial Asthma 3 chronic 
Bronchitis and emphysema were frequently coexist since they share 
common etiological factors and after many years chronic bronchitis get 
complicated by emphysema. 
 GOLD estimates suggested that Chronic Obstructive Pulmonary 
Diseases, sixth most common cause of death world wide at present, will 
be the third most common cause of death world wide by 2020. 1 
  
 
In India Chronic Obstructive Pulmonary Diseases is the second 
most common lung disorder after pulmonary tuberculosis. 19 
 This disease is frequently seen in middle-aged subjects.   Chronic 
Obstructive Pulmonary Diseases affects male more frequently than 
females because of smoking. 22 
 It is equally prevalent in rural and urban areas. 19 
 Increased smoking habits among younger people, increasing 
urbanization, increasing automobiles and emergence of industries 
leading to Air pollution that has definite impact on the epidemiology of 
Chronic Obstructive Pulmonary Diseases.  
 Low birth weight, malnutrition, recurrent respiratory infection in 
childhood also predisposed to Chronic Obstructive Pulmonary Diseases 
in future. 24 
 Spirometry is the most robust test of airflow limitation in patient 
with Chronic Obstructive Pulmonary Diseases. 3 
 A low FEV1 (FEV1 < 80%) with FEV1 / FVC ratio < 0.7 and       
un < 15% reversibility of airflow obstruction to broncho dialators is the 
diagnostic criteria for COPD. 2 
(FEV1 – Forced Expiratory Volume in 1 sec.  FVC – Forced Vital 
Capacity) 
  
 
This study, conducted at Thanjavur Medical College during the 
period of 2005 – 06 is first of its kind in this region, try to find out the 
age and sex incidence of Chronic Obstructive Pulmonary Diseases and 
incidence of various risk factor. 
 Further more this study is to elucidate the relationship of clinical 
symptom and spirometry abnormalities and also the incidence of right 
heart failure in Chronic Obstructive Pulmonary Diseases. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
 
  
 
 
 
 
 
 
AIM OF THE STUDY 
 
 
1. To study the age and sex distribution in Chronic Obstructive 
Pulmonary Diseases. 
2. To study the incidence of various risk factors in Chronic 
Obstructive Pulmonary Diseases. 
3. To correlate the clinical symptoms with spirometry abnormalities 
in Chronic Obstructive Pulmonary Diseases. 
4. To study the clinical incidence of Right Heart failure in Chronic 
Obstructive Pulmonary Diseases. 
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REVIEW OF LITERATURE  
 
 From the time of Laennec., et al through the first half of 20th 
century, mechanical explanations of Chronic Obstructive Pulmonary 
Diseases dominate.  The importance of cigarette smoking was not 
appreciated at that time.  But the observation “Chronic lung disease may 
cause heart failure even on other wise normal heart” was made at that 
time. 
 As early as in 1905 OPIE, et al suggested that enzymes and anti 
enzymes imbalance determines the risk of emphysema. 3 
 In 1934 Kountz and Alexander concluded that “It appears that 
heart is affected in most cases with emphysema” 3 
 In late 1950 Liebow et al proposed the vascular atrophy model of 
emphysema. 
 In 1956 the Medial Research Council in its journal used the term 
chronic bronchitis to describe conditions with chronic cough with 
expectoration of bronchial mucus hyper secretion.  When other causes 
like TB, PT Bronchiectasis were excluded. 
 In 1959 Higgins established the clear relationship between 
“Smoking and persistent cough and sputum production. 
 In 1960’s Gross and associates leads to the proteinase and 
antiproteinase hypothesis in emphysema observed in α1 antitrypsin 
deficiency. 
 In late 1960 Owen and Campell et al observed the pathological 
changes in airways due to cigarette smoking. 
 In 1971 Boushy SF et al., studied 108 patients of Chronic 
Obstructive Pulmonary Diseases.  The ECG was correlated with 
pulmonary function Test and haemodynamic data. 
 In 1972 Benjamin Burrows et al, done a seven year study of 50 
cases of Chronic Obstructive Pulmonary Diseases whose cardiac status 
had been evaluated by cardiac catheterization when they were stable, 
showed that their longevity was inversely related with pulmonary 
vascular resistance. 
In 1973 Bougly and Colleagues published a series of papers on 
prognosis factors in Chronic Obstructive Pulmonary Diseases and 
prognosis values of lung functions test in Chronic Obstructive 
Pulmonary Diseases. 
In 1981 Matthay et al listed the electro cardio graphic changes 
chracteristic of RV and RA enlargement in COPD and corpulmonale. 
In 1987 Danchin N et al., used 2D echocardiography to study 
right side cardiac parameter and RV hypertrophy and showed the 
correlation between Echo cardiography changes and clinical symptoms. 
In 1990 Migures M et al showed that usefulness of pulsed 
Doppler Echocardiography to detect pulmonary artery hypertension in 
patients with COPD. 
EPIDEMIOLOGY 
 Chronic Obstructive Pulmonary Diseases is responsible for 
considerable morbidity and mortality in the community especially 
among the older people.  As these disorder has a protracted course 
spanning over several years to decades, place a major burden to the 
resources of health care system. 
 COPD is of considerable public health importance as these 
diseases are to a great extent preventable. 
 Exacerbation of the COPD occurs more during winter season. 
PREVALENCE IN INDIA 
Chronic Obstructive Pulmonary Diseases is the second most 
common lung disorder after pulmonary tuberculosis.   
Incidence are Higher in males due to higher prevalence of 
smoking.  It is a disease of middle aged and elderly people, less 
common below the age of 35 years. 
Studies from North India, reported that the prevalence of chronic 
bronchitis was as high as 16% in people above 40 years from rural areas.  
Prevalence is more in North India than South India due to seasonal 
variability, particularly extremes of climate in North India. 
A study by Bhattacharya et al showed prevelance of chronic 
bronchitis in rural population aged more than 30 years was 57 / 1000 
there was a male prepondence which was higher with increasing age and 
pack years of smoking. 
PREVALENCE IN WESTERN COUNTRIES: 
 In USA, it is estimated that they are > 16 million case of COPD.  
About 14 million with chronic bronchitis and around 2 million with 
emphysema.  Male : Female ratio ranges from 4 – 6% / 1 – 3%. 
 In UK, a prospective study involving 40,000 medical 
practitioners, showed that death rate from chronic bronchitis was higher 
in smokers and increased with amount smoked. 
AETIOLOGY 
Chronic Obstructive Pulmonary Diseases is characterized by a 
reduced Forced Expiratory Volume in 1 second (FEV1) and an 
accelerated rate of decline of FEV1.  The reduction in FEV1 can occur 
by any of three pathways. 
1. Impaired childhood growth and development, with a lower 
peak in early adulthood and a normal rate of decline with 
aging eg. Early childhood infection and passive smoke 
exposure. 
2. Normal growth and development with premature peak but 
normal subsequent decline eg: astma and passive smoking. 
3. Normal growth and development and peak, with accelerated 
decline eg.: active smoking and to a lesser extent 
environmental exposures. 
 
RISK FACTORS: 
Smoking 
 Cigarette smoking is the most commonly identified correlate with 
chronic bronchitis during life.  Pipe and Cigar smokers have a higher 
mortality and morbidity rates for COPD shows a dose response 
relationship with the number of pack-years of tobacco consumed.  The 
British Thoracic Society guidelines suggest that most patients with 
COPD have at least 20 pack years smoking history.  An average 
cigarette smoker have high annual rate of decline in FEV1 of about 
50ml, which is nearly double the average value of 30ml in nonsmokers.  
In nonsmokers the decline in FEV1 begins at 30-35 years of age and this 
may occur earlier in smokers.  Stopping cigarette smoking does not 
produce a substantial improvement in FEV1 but the subsequent rate of 
decline is decreased. 
 Prolonged cigarette smoking impairs respiratory epithelial ciliary 
movement, inhibits function of alveolar macrohages and leads to 
hyperplasia and hypertrophy of mucus secreting glands.  Cigarette 
smoke also inhibits anti-proteases and causes polymorphonuclear 
leukocytes to release proteolytic enzymes.  Smoking is associated with 
increased airway responsiveness, which is associated with more rapid 
progression in patients with COPD.  Obstruction of small airway is the 
earliest demonstrable mechanical defect in a smoker. 
Air Pollution 
 Incidence and mortality rates of both chronic bronchitis and 
emphysema may be higher in industrialized urban areas.  Exacerbation 
of bronchitis are clearly related to periods of heavy pollution with sulfur 
dioxide and particulate matter. 
 In developing countries like India traditional cooking fuels such 
as wood, cow dung cake, etc., along with poorly ventilated houses are 
significant risk factors for chronic bronchitis. 
Socio Economic Status 
 Hrubec et al found a strong association between socio economic 
status based on occupation and respiratory symptoms in a study of 
twins.  In so many studies it was observed that an inverse relation 
between percapita income and obstructive lung disease. 
Occupation 
 Chronic bronchitis is more prevalent in workers who engage in 
occupation exposing them to either inorganic or organic dusts, or to 
noxious gases.  Surveys have found an accelerated decline in lung 
function in such workers eg, workers in plastic plants to exposure to 
Toluene disouganate etc.  Exposure to cadmium can increase the chance 
of development of emphysema and hence COPD. 
 
 
Recurrent Respiratory Infections 
 Frequency of acute respiratory illness are higher in patients with 
chronic bronchitis.  Epidemiological studies however implicate recurrent 
respiratory illness as one of the major factors associated with etiology as 
well as the progression of chronic airway obstruction. 
Airway hyper responsiveness and atopy: 
 Even though airway hyper responsiveness is a future of asthma 
many patient with COPD also share this feature but less than 15% of 
reversibility of obstruction to bronchodilators. 
Growth And Nutrition 
 Studies have shown that nutrition may affect both the growth and 
decline in ventilatory function.  There is also some evidence that server 
viral pneumonia early in life may lead to chronic obstruction, 
particularly in small airways. 
GENETIC FACTORS: 
α1, Antitrypsin Deficiency 
 α1 AntiTrypsin (α1AT) is a polymorphic glycoprotein responsible 
for the majority of anti-protease activity in the serum, whose synthesis is 
governed by a gene on 14q 32 chromosome.  The most commonest 
deficient allele termed ZZ (Cor PiZZ Phenotypel) results from a single 
amino acid substitution 342Glu → Lys, which causes spontaneous 
polymerization of the polypeptide, markedly impairing its release into 
circulation from the liver.   
It is commonly seen among people from European descent 1:2000 
to 1:7000 people, rate in people from African and Asian lineage. 
 α1 AT deficiency accounts for 2% of observed cases of 
emphysema.  Patients present with premature development of 
enphysema chronic bronchitis or bronchiectasis.  The patient usually 
presents with cough and dyspnea in the forth decade.  Nearly 80% had a 
family history of lung disease with autosomal recessive inheritance.  
The average decline of FEV1 is 100-130ml / yr for smokers and 50 to 
80ml / yr for ex-smokers of lifetime nonsmokers. 
 Pathologically panacinar emphysema predominates and 
radiographically changes are most marked in lower lobes.  Tobacco 
smoking is an extremely important cofactor for development of disease 
in α1 AT deficiency. 
 These patients are also at increased risk of hepatic cirrhosis. 
PATHOLOGY 
 The pathologic changes of COPD involves large and small 
airways and the terminal respiratory unit. 
  Small airways are the major sites of airflow limitation.  Small 
airways show a variety of lesions narrowing their lumina, including 
goblet cell hyperplasia, mucosal and submucosal inflammatory cells, 
edema, peribronchial fibrosis, intraluminal mucus plugs and increased 
smooth muscle. 
 In large cartilaginous airways chronic bronchitis is associated 
with hypertrophy of submucosal mucus producing glands.  Quantitation 
of this anatomic change is known as Reid index is based on thickness of 
submucosal glands to that of bronchial wall.  In patients with chronic 
bronchitis it is 0.44 ± 0.09 otherwise normally 0.52 ± 0.08. 
 Emphysema begins as an increase in the number and sizes of 
alveolar fenestrate and results in eventual destruction of alveolar septae 
and their attachments to terminal and respiratory bronchioles.  With 
centriacinar emphysema the distention and destruction are mainly 
limited to the respiratory bronchioles with relatively less changes 
peripherally in the acinus.  Panacinar emphysema involves both central 
and peripheral portions of acinus. 
PATHOGENESIS OF EMPHYSEMA  
Chronic exposure to cigarette smokes, fumes and dust may lead to 
inflammatory cell recruitment within the terminal air space of the lungs. 
Theses cells release elastolytic proteinases that damage the extra cellular 
matrix of the lung. 
In effective luner of other extra cellular matrix components of 
result in emphysema. 
 
 PATHOPHYSIOLOGY 
Airflow limitation:  
Airflow limitation and increased airway resistance may be caused 
by loss of elastic recoil during passive exhalation due to emphysema, by 
increased collapsibility of small airways through loss of radial traction 
on airways, or to increased resistance due to intrinsic narrowing of small 
airways. 
 
 
Hyperinflation:  
 The residual volume and the functional residual capacity (FRC) 
are almost higher than normal.  In addition prolongation of expiration is 
associated with obstruction which would lead to dynamic increase in 
FRC (dynamic hyperinflation). 
Dynamic hyperinflation contributes additionally to discomfort 
associated with air flow obstruction by flattening the diaphragm fiber 
length and a perpendicular insertion with the lower ribs. 
Impaired Gas Exchange: 
 Maldistribution of inspired air and blood flow is always present.  
When the mismatching is severe, impairment of gas exchange is 
reflected in the abnormalities of arterial blood gases.  Small airway 
narrowing causes a decrease in ventilation of their distal alveolar acini. 
When the alveolar capillaries remain intact, this results in mismatch of 
ventilation and perfusion leading to mild or moderate hypoxemia. 
Pulmonary Circulation in COPD 
 Pulmonary arterial hypertension develops late in the course of 
COPD.  With the development of hypoxemia and usually hypercapnia.   
It is the major cardiovascular complication of COPD and is associated 
with the development of right ventricular hypertrophy (cor pulmonale) 
and with poor prognosis. 
Factors contributing to the development of pulmonary artery 
hypertension in COPD 
(i) ABNORMAL BLOOD GAS TENSIONS 
Hypoxemia: 
 In COPD there is a negative correlation between oxygen 
saturation of the blood and pulmonary artery pressure.  Hypoxemia is 
known to be a potent arteriolar constrictor in the pulmonary circulation.  
As the severity of disease progresses in COPD there is more arterial 
desaturation correlation with an increase in pulmonary artery pressure.  
Exacerbation of COPD with hypoxemia are associated with acute 
worsening of pulmonary hypertension.  Pulmonary artery pressure (Ppa) 
can also increase acutely during the episodes of hypoxemia that occur 
during rapid eye movement of sleep, and it has been suggested that 
recurrent nocturnal pulmonary hypertension can result in pathologic 
changes in pulmonary vessels and fixed hypertenison. 
Hypercapnea: 
 In patients with COPD there is a positive correlation between 
arterial CO2 pressure (PaCO2) and pulmonary artery pressure.  The 
mechanism could be a change in lung mechanics due to hyperventilation 
induced by hypercapnea or the potentiation of hypoxic pulmonarly 
vascoconstriction. 
 
Acidemia: 
 Hypoxia and acidemia act synergistically to produce pulmonary 
vasoconstriction in patients with COPD.  Thus for a given oxygen 
saturation, the mean Ppa is higher with increasing arterial hydrogen ion 
concentration. 
(ii) EFFECTS OF ABNORMAL PULMONARY MECHANICS 
Changes in airway resistance may augment pulmonary vascular 
resistance and increase in pulmonary artery pressure, correlating with 
decrease in FEV1.   
(iii) EFFECTS OF INCREASED CARDIAC OUTPUT 
In patients with COPD (in whom the vascular bed may be 
reduced) even small increase in flow that occurs during exercise may 
increase pulmonary artery pressure. 
(iv) EFFECTS OF BLOOD VISCOSITY 
Polycythemia can develop secondary to chronic hyposemia in 
COPD patients, this contributes to blood viscosity which also adds up to 
the pulmonary arterial hypertension. 
(v) ROLE OF PULMONARY ENDOTHELIUM 
There is increasing evidence that endothelial dysfunction is an 
underlying factor in development of pulmonary artery hypertension.  
This may result in reduction in nitric oxide synthesis or release in 
response to hypoxemia.   
Thus the putative role of nitric oxide in preventing an excessive 
rise in pulmonary vascular tone, as a result of stimuli such as 
hypoxemia, may be lost in COPD.  It has also been suggested that nitric 
oxide may have an inhibitory effect on cell proliferation in the 
pulmonary vessel walls that therefore has a role in preventing the 
vascular remodeling that occurs in hypoxic COPD.  Circulating levels of 
endothelin – have been found to be increased in patients who have 
emphysema and pulmonary hypertension. 
PATHOLOGY 
 Changes in pulmonary circulation occurs characteristically in the 
peripheral arteries in patients with COPD.  An early is the increase 
intimal thickness in small pulmonary arteries that occur due to 
accumulation of smooth muscles that are laid down longitudinally along 
the length of the vessel.  Medical hypertrophy in muscular pulmonary 
vessels, has also been reported in patients of COPD who develop 
sustained pulmonary arterial hypertension.  Pulmonary thromboses may 
also occur in patients with COPD with may be secondary to peripheral 
airway inflammation. 
 Thus structural changes rather than simply hyposic 
vasconstriction is the major factory in the development of sustained 
pulmonary hypertension in patients with COPD. 
 
PULMONARY HAEMODYNAMICS IN COPD 
 Pulmonary haemodynamics in patients with COPD depend on the 
stage of disease.  In patients with mild COPD without severe hypoxemia 
or hypercapnia, pulmonary arterial pressure is usually normal or only 
slightly elevated when measured at rest but may rise abnormally during 
exercises. 
 Cardiac output is normal, as are right atrial and right ventricular 
end diastolic pressure.  As airflow limitation and arterial blood gas 
abnormalities, particularly when chronic hypoxemia and hypercapnia 
are present, pulmonary hypertension develops at rest and worsens on 
exercise. However in patients with severe COPD when the 
measurements are made in a clinically stable the pulmonary artery 
pressure is only modestly elevated. 
CONSEQUENCES OF PULMONARY HYPERTENSION IN 
COPD 
 Chronic bronchitis and emphysema usually coexist 
pathologically.  Those patients with either predominant chronic 
bronchitis or emphysema from a minority at the either ends of the 
disease spectrum of COPD. 
 The blue and bloated type also know as type B or nonfighter was 
though to characterize the bronchial type of disease.   
 
These patients had hypoxemia, hypercapnea and secondary 
polycythemia, they developed pulmonary hypertension relatively early 
in the course of disease.  Right ventricular hypertrophy / cor pulmonale 
ensure and repeated episodes of right heart failure occurred. 
 In contrast the pink and puffing variety also known as type A or 
fighter, were though to represent the emphysematous patients 
characterized by severe breathlessness, but with preservation of blood 
gas values and thus no pulmonary hypertension, at least until the later 
stages of disease. 
 It was now known that the degree of mucous gland hypertrophy 
indicative of chronic bronchitis was similar whatsoever the clinical 
pattern and that more than 50% of patients with blue and bloated clinical 
pattern had severe emphysema. 
THE NATURAL HISTORY OF UNTREATED PULMONARY 
HYPERTENSION IN COPD 
 
 The progression of pulmonary hypertension in COPD is slow.  
The elevation in pulmonary artery pressure is small and it rarely reaches 
the levels of primary pulmonary hypertension. Weitzenblum and 
colleagues found a change of 3mm Hg in the pulmonary artery pressure 
per year and 33% of patients showed a rise greater than 5mm Hg over 5 
years.  In these patients hypoxemia and hypercapnia also progressed. 
 Inspite of the slow progression the presence of pulmonary artery 
hypertension implies a poor prognosis. 
 One study shows that the 4 years survival rate was 40% in 
patients with pulmonary hypertenison compared to 72% in patients 
whose pulmonary artery pressure was normal (less than 20mg Hg). 
 The other variable which correlates significally with survival are 
PaO2, PaCO2, FEV1 and the presence of peripheral oedema.  Thus 
although studies have shown an association between the presence of 
pulmonary hypertension and the prognosis of COPD, pulmonary 
hypertension may simply be a reflection of the severity of the disease. 
COR PULMONALE 
 Cor pulmonale is defined as right ventricular hypertrophy and 
dilatation secondary to pulmonary hypertension caused by disease of the 
lung parenchyma and / or pulmonary vasculature, unrelated to both sides 
of heart. 
 The prevalence of right ventricular hypertrophy in a large 
European study showed that in increased as air flow limitation worsened 
in patients with COPD, being present in 40% of patients when, FEV1 
was < 1.0L and in 70% when FEV1 falls to 0.6L.  The prevalence of cor 
pulmonale is also higher in patients with hypercapnia hypoxemia and 
polycthemia. 
 Right ventricular contractility is maintained in patients with 
COPD when their condition is clinically stable, even in the presence of 
increased pulmonary arterial pressure.  But in patients with respiratory 
failure and peripheral oedema, the pulmonary arterial pressure is greater 
than that studied in stable state and the right ventricular contractility is 
decreased. 
 There is increasing evidence that the oedema which develops late 
in the course of the disease in patients with COPD may not be entirely 
due to right ventricular failure.  The key factor leading to changes in salt 
and water balance in patients with COPD is the development of 
hypoxemia and hypercapnia.  The most consistent factor in renal 
function in patients with hypoxic COPD, particularly those with oedema 
is a reduction in renal blood flow.  Hypercapnia reduces renal blood 
flow through catecholamine release and vial a nerually mediated action.  
Arginine vasopressin levels may be inappropriately high in patients with 
COPD.  There is also evidence of activiation of rennine-angiotensin-
aldosterone axis. Thus a complex interaction between pulmonary 
haemodynamics and changes in salt, water and hormonal homeostasis 
occurs in patients with hypoxic and hypercapnic COPD leading to 
peripheral oedema. 
 
 
CLINICAL FEATURES 
Symptoms 
 The characteristic symptoms of COPD are breathlessness on 
exertion, mostly accompanied by wheeze and cough, which is often but 
not invariably productive.  Most patients have a smoking history of at 
least 20 pack years before symptoms develop, commonly in the fifth 
decade. 
 Breathlessness is the symptom that causes most disability and in 
associated with loss of lung function over time.  It is usually first 
noticed on climbing hills or stairs.  The appearance of breathlessness 
indicates moderate to severe impairment of airway function.  By the 
time patient seeks medial help FEV1 has usually fallen to 1-1.5lt in an 
average male.  However, when the FEV1 has fallen to 30% or less of the 
predicted values breathlessness is usually present on minimal exertion. 
 In most patients with COPD cough precedes the onset of 
breathlessness.  Sputum is usually mucoid in character, but becoming 
purulent during exacerbations.  Volume is generally small and less than 
60ml per day.  As COPD progresses exacerbations becomes more 
frequent and severe. 
 Wheezing is present but is neither specific nor indicates the 
severity of obstruction. 
 Weight loss and anorexia are signs of severe COPD. 
Physical Signs 
 These are not specific to the disease and depend on degree of air 
flow limitation and over inflation.  In early disease the only abnormal 
findings is wheeze on forced expiration and a forced expiratory time 
prolonged beyond 6 seconds with more advanced disease the breathing 
pattern is characteristic with a prolonged expiratory phase.  Some 
patients adopting pursed-lip breathing on expiration which may reduce 
expiratory airway collapse.  The use of accessory muscles of respiration 
particularly stemomastoid is seen in advanced disease.  These patients 
adopt the position of leaning forward, supporting themselves with their 
aims to fix the shoulder girdle and allowing the use of pectoralis and 
latissimus dorsi to increase chest wall movements. (The tripod position). 
 In later stages the chest is often barell shaped, an increased 
anterior posterior diameter, horizontal ribs, prominence of the sternal 
angle and wide subcostal ange. An inspiratory tracheal tug may be 
detected.  The horizontal position of diaphragm also acts to pull on the 
lower ribs during inspiration (Hoover’s sign). 
 On percussion there is decreased cardiac and hepatic dullness, 
indicating over inflation. 
 Breath sounds may have a prolonged expiratory phase or may be 
uniformly diminished. 
 
RADIOLOGY 
Chest X-ray: 
 There are no specific features on plan chest-X-ray for chronic 
bronchitis. The features usually described are for emphysema. 
 Bronchial wall thickening seen as parallel line opacities on plain 
chest X-ray has been described in chronic bronchitis. 
 Radiographic signs for emphysema are: 
• Share-sheath treeches. 
• Low flattened diaphragm: The border of the diaphragm in the 
midclavicular line below the seventh rib. 
• Height of patients lung being greater than 29.9 cm. 
• An obtuse costophrenic angle. 
• Reduction in size and number of pulmonary vessels particularly in 
periphery of lung. 
• Heart shadow is vertical and narrow. 
• In lateral film increase in the retrosternal airspace. 
Computed tomography: 
 Has greater sensitivity and specificity than plain chest X-ray for 
emphysema but is rarely necessary except for diagnosis of 
bronchiectasis and evaluation of bullous lung disease. 
 
SPIROMETRY 
 Because of imprecisions of clinical findings, objective evaluation 
of presence, severity and reversibility of airflow obstruction is essential 
in the diagnostic evaluation of COPD. 
Spirometry is themost robust test of airflow limitation in patients 
with COPD. 
 Forced expiratory volume in one second (FEV1) is recommended 
as the measurement of choice in COPD because 
• FEV1 is reproducible and objective measurement. 
• It is simple and relatively quick to measure and can be measured 
at all stages of disease. 
• The forced expiratory maneuver records not only FEV1 but also 
FVC and FEV1 / FVC ratio less than 70% is diagnostic of airway 
obstruction. 
• Studies have shown FEV1 predicts future morbidity and mortality. 
• Serial measurement provides evidence of disease progression. 
Global initiative for chronic obstructive lung disease (GOLD) 
group has reclassified COPD in June 2003 on spirometric values. 
 
 
 
FLOW VOLUME LOOPS 
 Expiratory flow at 75% or 50% of vital capacity have been used 
as a measure of airflow limitation and provide complementary 
information to the usual volume time plot.  There are problems with the 
reproducibility of these measurements and hence not preferred for 
routine clinical use. 
Reversibility to bronchodilators 
 Reversibility tests are important because 
1. To help distinguish those patients with marked reversibility (at 
least 12% or 200ml of FEV1) who have underlying asthma. 
2. To aid with future management. 
3. The FEV1 after bronchodilator is the best predictor of survival. 
It is usually recommended that the response to bronchodilator be 
assessed either using repeated doses from metered dose inhaler or via 
the nebulised route. 
GAS TRANSFER FOR CARBON MONOXIDE 
 Gas transfer for carbon monoxide values are below normal in 
many patients with COPD and although there is a relationship between 
gas transfer and microscopic emphysema the severity of emphysema in 
an individual patient cannot be predicted from this. 
 
 
ARTERIAL BLOOD GAS ANALYSIS 
 Measurement of arterial blood gas is essential in patients with 
COPD to confirm the degree of hypoxaemia and hypercapnia and in 
acute exacerbation to determine the hydrogen ion concentration. 
OTHER TESTS 
 Patients with pulmonary hypertension or cor pulmonale with 
normal day time blood gases should be evaluated for nocturnal 
desaturation by overnight oximetry. 
 α1 AT level are not routinely needed but should be obtained for 
chronic airflow obstruction in non smokers, as well as COPD patients 
with bronchiectasis, cirrhosis without apparent risks, premature or 
bibasilar emphysema in patients under 50 years with unremitting disease 
and in individuals with family history of AT deficiency. 
METHOD OF ASSESSING CARDIAC FUNCTION IN PATIENTS 
WITH COPD 
 One of the major difficulties in assessing pulmonary 
haemodynamics and right ventricular function is the need to measure 
pressure and flow which involves the use of invasive techniques such as 
cardiac catheterizaiton. 
 More recently non invasive technique have been used to assess 
patients with COPD, these include radiography, electrocardiography, 
echocardiography, radionucleide ventriculography and magnetic 
resonance imaging. 
CLINICAL ASSESSMENT 
 Clinical examination is relatively insensitive as a means of 
detecting pulmonary hypertension or right ventricular dysfunction in 
patients with COPD, as clinical signs are often obscured by 
hyperinflation of the chest. 
 Physical signs that indicate the presence of pulmonary 
hypertension are accentuated pulmonary component of S2 early systolic 
click, an early diastolic murmur of pulmonary regurgitation etc. 
 Jugular venous pressure are difficult to assess in patients with 
COPD because of large swings in intrathoracic pressure. 
 Peripheral oedema can be due to other causes (such as 
hypoalbuminemia). 
 A systolic left parasternal heave indicates right ventricular 
hypertrophy, extra heart sounds and murmur of tricuspid regurgitation 
suggests right ventricular dysfunction, but these are again modified by 
hyperinflation. 
CHEST X-RAY 
 The presence of pulmonary arterial hypertension in patients with 
COPD has been shown to relate to the width of right descending 
pulmonary artery ≥ 20mm.  In addition high value for hilar 
cardiothoracic ratio was 95% sensitive and 100% specific for the 
presence of pulmonary hypertension in patients with COPD.  
These may be useful as an initial screening test for the presence of 
pulmonary hypertension, they cannot be used to predict the level of 
pulmonary artery pressure in individual patients. 
ELECTROCARDIOGRAPHY 
 The voluminous lungs have an insulating effect and there by 
diminishing the electrical transmission of electrical potentials to the 
electrodes.  The heart descends to a lower position in the thorox due to 
lowering of diaphragm, altering the position of heart relative to the 
conventional electrodes. 
 The common electro cardiographic abnormalities in COPD and 
COPD with right heart involvement 10 
• Decreased magnitude of electro cardiographic deflections. 
• P-waves with right atrial enlargement p-pulmonale i.e., tall 
peaked P waves in II, III and AVF (P value > 2.5mm) 
• QRS abnormalities: Right axis deviationi and QRS > 900. At 
times with extreme north west QRS axis there is the S1S2S3 
syndrome.  In precordial leads there is a general loss of R wave 
amplitude in all precordial leads.  With right ventricular 
hypertrophy R/S amplitude in V6 < 1.  Tendency for incomplete 
right bundle branch block. 
Electrocardiography appears to be specific but has a low 
sensitivity of picking up right ventricular hypertrophy. 
ECHOCARDIOGRAPHY 
 Because of the deficiencies of clinical examination in detecting 
pulmonary artery hypertension in patients who have COPD and because 
pulmonary artery pressure (Ppa) is such as good predictor of prognosis 
in these individuals, a number of attempts have been made to develop 
noninvasive methods to estimate it.  Echocardiographic measurements 
of systolic and diastolic and pulmonary pressures have been shown to 
correlate with Ppa measured by catheterizaiton studies. 11 
 The most useful and accurate method of estimating pulmonary 
artery pressure in patients with chronic obstructive pulmonary disease is 
systolic transtricuspid gradient calculated from tricuspid regurgitation 
detected by continuous wave Doppler echocardiography.  Continuous 
wave Doppler determination of tricuspid regurgitation jet velocity and 
application of modified Bernoulli’s equation (TG = 4V2, in which V is 
the velocity of tricuspid regurgitation jet and TG is the systolic right 
ventricular to right atrial pressure gradient across the tricuspid valve) 
permits reliable estimation of pulmonary artery pressure is low.  Several 
studies have shown correlation between echocardiographic 
measurements of pulmonary artery pressure and pressures measured at 
cardiac catherterization. 
 Two dimensional echocardiography can be used to assess right 
ventricular dimensions and wall thickenings and hence to detect right 
ventricular volume over load in patients with COPD. 
 Echocardiography can again be used to assess progression of 
disease or response to treatment by serial measurements of pulmonary 
artery pressure and right heart parameters. 
MANAGEMENT OF COPD 
I. Non Pharmacological measures. 
II. Pharmacological measures. 
I. Non Pharmacological Measures 
Health education: it can play a role in improving stills, ability to 
cope with illness. 
i. Smoking cessation. 
ii. Basic information about COPD. 
iii. Self management skills. 
II. Pharmacological Measures 
i. Nicotine replacement therapy in the form of gum, 
transdermal patch or inhaler is helpful in quitting smoking. 
ii. The use of bupropion, a noradrenergic antidepressant, is 
associated with better abstinence rates. 
iii. Bronchodilators are the main stay in the management of 
COPD. 
iv. Inhaled therapy preferred. 
v. Choice between β2 agonist, anticholinergic theophylline or 
combination theraphy depends on availability and 
individual response in terms of symptom relief and side 
effects. 
vi. Bronchodilators are prescribed on as needed, or on a 
regular basis to prevent or reduce symptoms depending on 
stage. 
vii. Long acting bronchodilators are more effective and 
convenient. 
viii. Combining bronchodilators improve efficacy and decrease 
the risk of side effects compared to increasing the dose of a 
single bronchodilator. 
GLUCOCORTICOSTERIODS 
 Inhaled glucosteroids are appropriate for symptomatic COPD 
patients with an FEV1 < 50% predicted (Stage III & IV). 
 Present guidelines recommend a trial of 6 weeks to 3 months with 
inhaled steroids to identify patients who may benefit from long term 
inhalation steroid therapy.  Long term treatment with oral steroids is not 
recommended in COPD. 
 
 
HOME OXYGEN THERAPY (HOT) 
 
 Long term oxygen administration (> 15 hours per day) to patients 
with chronic respiratory failure has been shown to increase survival. 
 
 In Nocturnal oxygen treatment trial it has been shown a reduction 
in pulmonary arterial pressure on exercise after 6 months with either 
continous or nocturnal oxygen therapy.  This study also showed that 
survival over a period of 8 years was related to the decrease in mean 
pulmonary arterial pressure during the first 6 months of treatment. 
 
 Long term oxygen therapy is introduced in stage IV who have 
• PaO2 at or below 55 mmHg or SaO2 at or below 88% with or 
without hypercapnia or 
• PaO2 between 55 mmHg and 60 mmHg if there is evidence of 
pulmonary hypertension, peripheral oedema suggesting 
congestive heart failure, or polycythemia (Haematocrit > 55%). 
Home oxygen therapy can be supplied in the form of compressed 
gas cylinders or oxygen concentrators.  Oxygen concentrators are most 
convenient and cost effective. 
 
 
 
OTHER PHARAMACOLOGIC TREATMENT 
 
α1 ANTITRYPSIN AUGMENTATION THERAPY: 
 Young patients with severe α1 AT deficiency and established 
emphysema may be candidates for the same. 
 
ANTIBIOTICS: 
 Recommended only for exacerbation of Chronic Obstructive 
Pulmonary Diseases. 
 
VACCINES:  
Influenza vaccines can reduce serious illness and death in elderly 
Chronic Obstructive Pulmonary Diseases patients by about 50%. 
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MATERIALS AND METHODS 
 This study was conducted at Department of Medicine and 
Thoracic Medicine, Thanjavur Medical College during the period of 
2005 – 06. 
TOTAL NUMBER OF PATIENTS IN THIS STUDY: - 
Number of patients in this study is 60 cases. 
INCLUSION CRITERIA: - 
The cases in this study have following characters: 
(i) Cases between the age group of 30 – 80 years of both sexes. 
(ii) These cases having the symptoms suggestive of chronic 
airway obstruction like cough, cough with expectoration of 
sputum of more than 2 years duration, dyspnoea, and with (or) 
without swelling of both legs. 
(iii) Cases in whom clinical diagnosis of COPD was made. 
(iv) All the cases were subjected to spirometry and the presence of 
COPD was confirmed by post bronchodilator spirometry 
values of  
i. FEV1 < 80%. 
ii. FEV1 / FVC < 0.7. 
iii. Reversibility of obstruction < 15%. 
(FEV1 – Forced Expiratory Volume in 1 sec.  FVC – Forced Vital 
Capacity) 
EXCLUSION CRITERIA: - 
Case with history of the following diseases were excluded; 
(i) Bronchial Ashma.  (ii) Pulmonary Tuberculosis. 
(iv) Suppurative lung disease. (iv) Systemic Hypertension. 
(v) CAHD.       (vi) Primary Pulmonary  
Hypertension. 
(vii) Valvular Heart disease. (viii) Sleep Apnoea syndrome. 
PROCEDURE: 
With above inclusion and exclusion criteria a proforma was 
prepared to meet the objectives of the study. 
GEOGRAPHIC DISTRIBUTION: 
Patients were from Thanjavur Town, Pattukottai, and rural areas 
of Thanjavur, Pattukottai and Ariyalur districts. 
All the patients were subjected as follows; 
1) Detailed History. 
2) Smoking History. i) Age at which smoking was started. 
ii) Pack – years was calculated by 
formula. 
   No. of Cigarettes smoked / day          
Pack Year =--------------------------------------  x   No. of years of smoking 
                20 
3) General examination and examination of Respiratory system, 
and other systems. 
4) Examination specifically for signs of right heart failure like 
raised JVP, congestive hepatomegaly and pedal edema. 
5) Conventional 12 lead Electro cardiography was taken for ECG 
changes of COPD and Right Heart failure. 
6) X-ray chest PA view and left lateral view. 
7) Spirometry: - Spirometry was performed when the patient was 
clinically stable. 
Test was performed with the patient comfortably seated, with 
clothes loosened.  The patients were instructed to take a deep inspiration 
then close the lips around the mouth piece and blow out as hard and fast 
as possible, following deep inspiration. 
Volume was obtained on the vertical axis of recording paper and 
time on the horizontal axis.  The curve which was obtained is referred to 
as forced vital capacity curve. 
Forced Vital Capacity (FVC) is the volume of air that can be forcibly 
exhaled (as fast as possible) after a maximal inspiration.  It is expressed 
in litres. 
Forced Expiratory Volume in one second (FEV1) 
 It is defined as the volume of air expelled in the first second, from 
the start of maximum expiratory effort of the forced vital capacity.  It is 
expressed in litres or percentage of predicted.  
Forced expiratory volume in one second as a percentage of forced 
vital capacity (FEV1 / FVC) 
 It is the percentage of forced vital capacity which is expelled in 
the first one second of maximal expiratory effort. 
By using spirometry results patients were classified based on 
GOLD staging of COPD.  Severity of clinical symptoms were correlated 
with GOLD stagning of COPD. 
Pack Years of smoking was compared with severity of COPD. 
Patients who showed clinical sign of right heart failure where 
subjected to Echo cardiography for confirmation.  In echocardiography 
Mean maximum TR velocity was recorded in mt/sec and inserted into 
the modified Bernoulli’s equation (4v2), thus calculating the trans 
tricuspid pressure gradient (TTPG) and the pulmonary artery pressure. 
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RESULTS AND OBSERVATION 
The results collected from this study was tabulated into different 
variates and incidence of each variate was calculated in percentage. 
Table – 1 
Age 
in 
Years 
Male Percentage Female Percentage Total Percentage 
31-40 3 5.5% - 0% 3 5% 
41-50 5 9.2% - 0% 5 8.3% 
51-60 16 29.6% 2 33.3% 18 30% 
61-70 21 38.8% 3 50% 24 40% 
71-80 9 16.6% 1 16.6% 10 16.6% 
Total 54 100 6 100 60 100 
 
 From the above table it is observed that the majority of cases 
among males were between 61 – 70 years of age constituting 38.8% and 
the minimum number of cases were in the age group of 31 – 40 
constituting 5.5%. 
 Among females the majority of cases were in the age group of 61 
– 70 years constituting 40% and nil cases were observed in the age 
group of 31 – 50 years. 
 Both sexes put together the maximum cases were in the age group 
of 61 – 70 years constituting 40% of total cases and minimum cases 
were observed in the age group of 31 – 40 years which constituted 5% 
of total cases. 
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Sex distribution: 
Table – 2 
SEX No. of cases Percentage 
Male 54 90% 
Female 6 10% 
Total 60 100% 
 
From the above table, it is observed that the majority of the 
patients in this present study were belong to male sex.   
The male to female ratio was 9:1. 
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GEOGRAPHICAL DISTRIBUTION: 
Table – 3  
Area No. of cases Male Female Percentage 
Rural 42 37 5 70% 
Urban 18 17 1 30% 
Total 60 54 6 100% 
 
 It is observed from the above table 42 out of 60 cases were from 
the rural areas constituting 70% of the total cases. 18 cases from the 
urban area constituted only 30% of the total. 
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RISK FACTORS 
Table – 4 
Risk factor Male % Female % Total Percentage 
Active 50 92.5%   52 
Smoking 
Passive   2* 33.3%  
86.6% 
Air pollution 6 11.1% 2 33.3% 8 13.3% 
Chronic 
Respiratory 
Infection 
14 25.9% 3 50% 17 28.3% 
Allergy 4 7.4% 1 16.6% 5 8.3% 
 
(* Life partners of this two female patients were heavy smokers more  
     than 20 pack-years of smoking). 
 From the above table it was noted that major risk factor for COPD 
in males constituted 92.5% in males and 86.6% of total cases.   
Chronic respiratory inspection which constituted 50% of risk 
factor in females and 28.3% of total cases. 
Air pollution constituted 13.3% of risk factor followed by allergy 
with constituted 8.3%. 
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INTENSITY OF SMOKING 
Table – 5  
Pack year No. of patients Percentage 
10 – 20 2 4% 
20 – 30 38 76% 
30 – 40 10 20% 
 
 From the above table it can be observed that the majority of 
patients had more than 20 pack years of smoking which constituted 96% 
of total cases. 
 All the patients in this table were active smokers and all the 
patients were male. 
 
 
 
 
 
 
 
 
  
DURATION OF DISEASE 
Table – 6 
Disease Duration Males Females Total Percentage 
2 – 5 years 2 - 2 3.3 
6 –10 years 4 - 4 6.6 
11 – 15 years 19 3 22 36.6 
16 – 20 years 23 2 25 41.6 
> 20 years 6 1 7 11.6 
Total 54 6 60 100% 
 
 From the above table it is observed that majority of patients had 
more than 10 years duration of disease. 
 Maximum number of cases were seen 16 – 20 years duration of 
disease constituting 41.6% of cases. 
 
 
 
 
 
  
DISTRIBUTION OF SYMPTOMS 
Table – 7 
Symptoms No of patients Percentage 
Cough 60 100% 
Cough with expectoration of 
sputum 56 93.3% 
Wheeze 46 76.6% 
Breathlessness 52 86.6% 
Swelling both legs 5 8.3% 
 
 From the above table it is noted that all the patients in this study 
had cough. Cough was the major symptom constituted 100% in this 
study.   
Cough with expectoration of sputum was present in 93.3% of 
cases. 
Breathlessness which constituted 86.6% of cases. 
Wheeze which constituted 76.6% of cases. 
Swelling of both legs were observed in 8.3% of cases. 
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DISTRIBUTION OF CLINICAL SIGNS 
Table – 8 
Clinical signs No. of patients Male Female Percentage 
Cyanosis  4 3 1 6.6% 
Polycythemia 2 1 1 3.3% 
Accessory muscles 
working  24 20 4 40% 
Pedal oedema 5 4 1 8.3% 
Raised JVP 5 4 1 8.3% 
Congestive 
Hepatomegaly 5 4 1 8.3% 
 
 From the above table it is observed that active accessory muscles 
of respiration (inter costal in drawing) was the major clinical sign 
observed in 40% of the cases. 
 In this study polycythemia was observed in 3.3% of cases. 
 Pedal oedema, Raised JVP and Congestive Hepatomegaly were 
observed in 8.3% of cases. 
 
 
 
  
DISTRIBUTION OF RADIOLOGICAL FINDINGS 
Table – 9 
Chest x-ray No. of patients Percentage 
Low flattened diaphragm with 
hyperinflated lungs 39 65 
Obtuse costo phrenic angle 30 50 
Reduction in no and size of 
pulmonary vessels in periphery 12 20 
Normal 12 20 
 
 From the study it is observed that Low flattened diaphragm with 
hyperinflated lungs was the major radiological feature present in 65% of 
cases. 
 50% of cases were shown obtuse costo phrenic angle in chest      
x-ray. 
 20% of the patients in this study had Normal x-ray chest. 
 
 
 
 
 
 
  
 
DISTRIBUTION OF ECG CHANGES IN VARIOUS STAGES OF 
COPD 
Table – 10 
ECG changes Stage of 
COPD 
(GOLD 
criteria) 
Poor ‘R’ 
Wave 
progression 
in V1 – V6 
‘P’ 
Pulmonale 
QRS > 
+ 900 in 
frontal 
plane 
R/S < 
1 in 
V5 V6 
V6 < 
5 mm Total 
Stage I  - - - - - - 
Stage II  3 - - - - 3 
Stage III  5 0 0 - - 5 
Stage IV 6 5 5 3 3 22 
Total 14 5 5 3 3 30 
 
 From the above table it is observed that more number of ECG 
changes were seen in patients in Stage IV of COPD. 
 There was no ECG changes observed in patients with Stage I of 
COPD. 
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DISTRIBUTION OF ECG CHANGES 
Table – 11 
ECG changes Male Female Total Percentage 
Poor ‘R’ Wave progression in 
V1 – V6 
12 2 14 23.3% 
‘P’ Pulmonale 4 1 5 8.3% 
QRS > + 900 in frontal plane 4 1 5 8.3% 
R/S < 1 in V5 V6 2 1 3 5% 
V6 < 5 mm 2 1 3 5% 
 
From the above table it is observed that most frequent ECG 
abnormality in this study was poor progression of ‘R’ wave which was 
observed in 23.3% of cases. 
8.3% of cases showed evidence of cor pulmonale like ‘P’ 
Pulmonale and right axis deviation. 
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DISTRIBUTION OF CASES IN GOLD STAGING OF COPD 
Table – 12 
No. of cases 
GOLD stage of 
COPD Severity 
Male Female Total 
Percentage 
Stage I FEV1 ≥ 80% Mild 1 1 2 3.33% 
Stage II               
Fev1   50% – 80% 
Moderate  17 1 18 30% 
Stage III            
FEV1   30% – 50% 
Severe 31 3 34 56.6% 
Stage IV            
FEV1   < 30% 
Very 
Severe 5 1 6 10% 
 
From the above table, majority of the patients in the study were 
Gold Stage III of COPD showing severe airflow obstruction           
(FEV1 30% - 50%).   
10% of the patients showed FEV1 < 30% very severe air flow 
obstruction belonged to Stage IV of COPD. 
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DISTRIBUTION OF RIGHT HEART FAILURE IN COPD 
Table – 13 
Total No. of patients Patient with clinical signs of Right Heart Failure 
Male Female Total Male Female Total 
Percentage 
54 6 60 4 1 5 8.33% 
  
 From the above table it is observed that 5 cases having the clinical 
features of right heart failure constituting 8.33% of total. 
 All the 8.33% are also proved by echocardiography. 
 
 
 
 
 
 
 
 
 
 
 
  
DISTRIBUTION OF RIGHT HEART FAILURE IN DURATION 
OF DISEASE 
Table - 14 
No. of cases 
Duration of disease 
Male Female 
2 – 5 years - - 
6 –10 years - - 
11 – 15 years - - 
16 – 20 years 1 - 
> 20 years 3 1 
Total 4 1 
 
 From the above table it is observed more number of patients with 
right heart failure having disease more than 20 years of duration 
constituting 80% of the total cases of right heart failure in COPD. 
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DISCUSSION 
1. Total number of cases were 60 in this study. 
AGE AND SEX: 
2. In the present study maximum number of cases were in the age 
group of 61-70 years.   This coincides well with the various study 
as follows, 
i) Wig K.L Guleira K. S et al 1964 study showed maximum 
number of cases in 55-65 years. 20  
ii) Higham MA Dawson et al at 2001 showed maximum 
number cases in 61-70years. 52 
iii) Suzzane Hurd et al showed maximum number of cases in 
60-70 years. 4 
3. In this study, it was noted the incidence of COPD was higher in 
males than females with male to female ratio of 9:1. 
Male cases accounted for 90% of the total cases in this study. 
This finding also coincides with the following studies,  
1. Trivedi H.S. et al study showed 80% of cases were 
male. 46 
2. Mieguere et al showed 93% of cases were male. 44 
 
  
 
 
GEOGRAPHICAL DISTRIBUTION: 
In this study it is observed that 70% of patients were from rural 
areas and 30% were from urban areas. 
 The study by Bhattacharya S.N. et al, 1975, also made similar 
observation. 21 
Anderson et al, 1963, made similar observation in his study. 54 
In spite of heavy Air pollution, the urban areas contributed only 
30% of the cases in this study. 
RISK FACTOR: 
Among the various risk factors Smoking is the major risk factor 
accounted for 87% of the causative risk factor in this present study. 
Ashley F, Kannel WB et al, 1975, made similar observation. 54 
 Burrows et al, 1979, made similar observation. 25
 
Intensity of smoking was expressed in pack-years in this study.  
As the number of pack-years more than 20, increased predisposition to 
COPD was observed in many studies.   
In this study, most of the patients were 20-30 pack-years of 
smoking constituting 96% of the total. 
Higgins ITT et al, 1959, observed in his study 86% patients were 
more than 30 pack-years of smoking. 55  
  
 Chronic respiratory infection which constituted 28.3% was the 
second major risk factor observed in this study, followed by Air 
Pollution and Allergy. 
 Burrows B et al, 1977, also made similar observation.  In his 
study Chronic respiratory infection constituted 35%. 56 
 Air pollution constituted 13.3% of risk factor and Allergy 8.3% of 
risk factors. 24 
 
DURATION OF DISEASES: 
 In this present study of most of the cases were above 10 years of 
duration of the disease. 
 Barnes BJ et al, 1999, in his study observed 55% had more than            
15 years. 57 
 
Symptoms: 
 In this study cough and cough with expectoration of sputum was 
observed in 100% and 93% of cases respectively 
 Burrows et al, 1979, made in his study 96% of patients had cough with 
exportation of sputum. 25 
 Dyspnoea was observed in 86.6% cases. 
 Altose MD et al, 1985, observed 90% of cases had dyspnoea. 58 
 
 
  
Physical signs: 
 This study observed acting accessory muscles of respiration was the 
major physical sign observed in 40% of cases. 
 Polycythemia (Secondary to hypoxia) was observed in only 3.3% of 
cases.  
 Pedal oedema raised JVP and congestive hepatomegaly observered in 
8.3% of cases. 
Chest X-ray PA view: 
 In this present study most common radiological finding in chest X-ray 
PA view was hyper inflated lungs with low flattened diaphragm which 
constituted 65% of cases. 
 Thurlbeck WM et al, 1970, observed in his study 78% of the patients 
showed radiological evidence of emphysema with chronic bronchitis. 59 
 Normal X-ray chest was observed in 20% of cases. 
Electrocardiography: 
 By electrocardiography poor progression of ‘R’ Wave was the 
most frequent abnormality detected in this present study constituted 
23.3%.   
8.3% of cases showed ‘P’ pulmonale and QRS axis > + 900  
R/S < 1 in V5 -V6 observed in 5% of cases.   
R wave in V6 < 5 mm was observed in 3.3% of cases. 
  
Boushy SF et al., 1971, in his study observed that ‘P’ pulmonale 
and QRS axis > + 900 were the major ECG changes present in 12.5% of 
the patient. 10 
 It was observed from this study more number of cases with ECG 
changes were seen in Stage IV COPD.  Which denoted that as the 
severity of COPD increases, ECG changes also increases. 
SPIROMETRY: 
 In the study most number of patients were in GOLD Stage III 
COPD which constituted 56.6% of cases. The study by Higham et al 52 
showed that majority of patients were in Stage III (BTS Scheme for 
COPD)  constituted 57 – 58% of cases. 
 Renzeti AD et al, 1966 observed 76% of his cases belong to 
moderate to severe stages of COPD. 49 
Right Heart Failure: 
 In this study it is observed that 8.3% of cases showed clinical 
evidence of right heart failure.  All the patients who showed the clinical 
evidence of right heart failure were subjected to echocardiography and 
confirmed the presence of right heart failure. 
 Mattay R et al, 1981, observed that 12.5% of his cases were 
showed evidence of cor pulmonale. 16 
 
 
  
SUMMARY 
In this study on Chronic Obstructive Pulmonary Diseases the 
following facts were observed. 
COPD is the disease of aged as evidenced by majority of patients 
in the present study were belong to the age group of 50 – 80 years. 
COPD has male predominance as evidenced by 9:1 ratio of Male 
to Female due to high prevalence of smoking habits observed in males.  
Cigarette smoking was the major risk factor for COPD in this 
study. 
Cough / Cough with expectoration of sputum was the major 
clinical symptom observed in this study. 
Acting accessory muscles of respiration with pursed lip breathing 
was the major clinical sign observed in this study. 
Spirometry is the mandatory investigation to diagnose and assess 
the severity of COPD. 
Most number of cases had severe airway obstruction which was 
not reversible. 
High flattened diaphragm and hyper lucent lungs were the most 
common chest x-ray finding observed in this study. 
Poor progression of ‘R’ wave in chest leads, P Pulmonale,       
QRS > + 900,  R wave in V6 < 5mm and R/S < 1 in V5 V6 were the ECG 
changes observed in this study. 
The clinical incidence of Right heart failure in COPD in this study 
was 5% which was confirmed by ECHO. 
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CONCLUSION 
 
1. Chronic Obstructive Pulmonary Diseases is a preventable disease 
as smoking is the major risk factor for Chronic Obstructive 
Pulmonary Diseases. 
2. Spirometry is mandatory to diagnose and assess the severity of 
Chronic Obstructive Pulmonary Diseases FEV1 was the single 
most important parameter in spirometry to diagnose Chronic 
Obstructive Pulmonary Diseases along with the less than 15% of 
reversibility of airflow obstruction to bronchodilators. 
3. Severity of Chronic Obstructive Pulmonary Diseases has direct 
relation with incidence of ECG changes in Chronic Obstructive 
Pulmonary Diseases. 
4. Clinical signs of right heart failure in Chronic Obstructive 
Pulmonary Diseases were effective in screening the patients for 
cor pulmonale. 
5. Right heart failure denotes severity and duration of Chronic 
Obstructive Pulmonary Diseases. 
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PROFORMA 
STUDY ON COPD 
 
NAME:     AGE:   SEX:    M/F 
ADDRESS:        I.P / O.P. NO.: 
OCCUPATION:    ECONOMY CLASS: High 
          Middle 
          Low 
 
PRESENTING SYMPTOMS:     DURATION 
• Cough 
• Cough with expectoration of sputum 
• Breathlessness 
• Wheeze 
• Chest pain 
• Fever 
• Haemoptysis 
• Both Legs Swelling  
• Others (Specify) 
RISK FACTORS AND TRIGGERS: 
• Smoking 
• Air Pollution like, Smoke / Fumes / Dust 
• Recurrent respiratory infection. 
• Atopy and Allergy 
 
  
 
SMOKING HISTORY: ♦ Active  ♦ Passive 
Active: ♦ Cigarette / Ciger / Beedi 
  ♦ Age at smoking started. 
 ♦ Intensity of smoking in Pack-years. 
Passive: ♦ Father / Husband / Son / Other (Specify Relation) 
  ♦ Pack-year of smoking 
Family History:  (A) Bronchial asthma      (B) COPD 
 
OTHER DISEASES: 
♦ Pulmonary TB ♦ CAHD ♦ HT  ♦DM    ♦ Valvular Heart disease 
GENERAL EXAMINATION: 
Clinical signs: 
♦ Anemia  ♦ Polycythemia   ♦ Cyanosis 
♦ Accessory muscles of respiration active / normal 
♦ Pursed lip breathing present / absent 
♦ Lymphnodes  ♦ Pedal oedema  ♦ JVP 
Vital signs: 
PR:   BP:   RR: 
Examination of systems: 
 RS:  Inspection 
   Palpation  
   Percussion 
   Auscultation 
 CVS: 
 P/A: Congestive hepatomegaly  present / absent 
  
 CNS: 
INVESTIGATIONS: 
♦ Urine   i) Alb.  ii) Sugar 
♦ Blood i) TC  ii) DC  iii) Hb% iv) ESR 
♦ Blood Sugar 
  Urea 
♦ Chest X-ray   i) PA View    ii) Left Lateral view 
 
♦ Spirometry 
GOLD Stage FEV1 FEV1 / FVC 
Stage I   
Stage II   
Stage III   
Stage IV   
 
♦ ECG i) Normal 
  ii) Poor progression of ‘R’ wave in chest leads 
  iii) ‘P’ Pulmonale 
  iv) QRS > + 900 
  v) R / S in V5 - V6 < 1 
  vi) V6 R < 5mm 
♦ Echo: 
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KEY TO MASTER CHART 
i.  P / Y – Pack Years 
ii.  C.R.I. – Chronic Respiratory Infection 
iii.  SYMPTOMS 
a – Cough 
b – Cough with expectoration of sputum 
c – Wheeze   
d – Breathlessness 
e – Both Legs swelling 
iv.  SIGNS 
a – Cyanosis 
b – Polycythemia 
c - Accessory muscles working 
d - Pedal oedema 
e - Raised JVP 
f - Congestive Hepatomegaly 
v.  ECG CHANGES 
  
a – Poor ‘R’ Wave progression in V1 – V6 
b - ‘P’Pulmonale 
c - QRS > + 900 in frontal plane 
d - R/S < 1 in V5 V6 
e - V6 < 5 mm 
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